The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 450-456 , April 2008

Development of a Combined Heart and Carotid Artery Transplant Model to Investigate the Impact of Acute Rejection on Cardiac Allograft Vasculopathy

  • Behzad Soleimani, MD, MRCP, FRCS(C-Th)

      Affiliations

    • Department of Cardiac Surgery, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    • ,
  • Fumin Fu, MD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
    • ,
  • Philip Lake, PhD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
    • ,
  • Victor C. Shi, MD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
    • Corresponding Author InformationReprint requests: Victor C. Shi, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080. Telephone: 862-778-8300. Fax: 973-781-8265.

Received 26 July 2007 ,Revised 23 December 2007 ,Accepted 12 January 2008.

References 

  1. Billingham ME. Graft coronary disease: the lesions and the patients. Transplant Proc. 1987;19(4 suppl 5):19–25
  2. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors (Cardiac Transplant Research Databasem). J Heart Lung Transplant. 1998;17:744–753
  3. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol. 2000;190:300–309
  4. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115–126
  5. Arai S, Teramoto S, Senoo Y. The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. J Heart Lung Transplant. 1992;11:757–762
  6. Mennander A, Tiisala S, Paavonen T, Halttunen J, Hayry P. Chronic rejection of rat aortic allograft (IIAdministration of cyclosporin induces accelerated allograft arteriosclerosis). Transpl Int. 1991;4:173–179
  7. Mehra MR, Ventura HO, Chambers R, et al. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol. 1995;26:1537–1544
  8. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts (ITime course and immunogenetic and immunopathological considerations). Am J Pathol. 1994;144:260–274
  9. Armstrong AT, Strauch AR, Starling RC, Sedmak DD, Orosz CG. Morphometric analysis of neointimal formation in murine cardiac allografts. Transplantation. 1997;63:941–947
  10. Tanaka M, Fedoseyeva EV, Robbins RC. Graft coronary artery disease in murine cardiac allografts: proposal to meet the need for standardized assessment. J Heart Lung Transplant. 2005;24:316–322
  11. George JF, Pinderski LJ, Litovsky S, Kirklin JK. Of mice and men: mouse models and the molecular mechanisms of post-transplant coronary artery disease. J Heart Lung Transplant. 2005;24:2003–2014
  12. Orosz CG. Considerations regarding the contributions of B cells to chronic allograft rejection in experimental animal models. J Heart Lung Transplant. 2000;19:634–637
  13. Shi C, Russell ME, Bianchi C, Newell JB, Haber E. Murine model of accelerated transplant arteriosclerosis. Circ Res. 1994;75:199–207
  14. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice (The role of H-2D, H-2K, and non-H-2 antigens in rejection). Transplantation. 1973;16:343–350
  15. Shi C, Lee WS, He Q, et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A. 1996;93:4051–4056
  16. Ardehali A, Billingsley A, Laks H, Drinkwater DC, Sorensen TJ, Drake TA. Experimental cardiac allograft vasculopathy in mice. J Heart Lung Transplant. 1993;12:730–735
  17. Kobashigawa JA, Miller L, Yeung A, et al. Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. Sandoz/CVIS Investigators. J Heart Lung Transplant. 1995;14:S221–S226
  18. Jimenez J, Kapadia SR, Yamani MH, et al. Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant. 2001;20:393–398
  19. Stoica SC, Cafferty F, Pauriah M, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant. 2006;25:420–425
  20. Valantine H. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. J Heart Lung Transplant. 2005;24(4 suppl):S191–S195discussion S210–1
  21. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med. 1990;322:510–517
  22. Yin D, Fathman CG. CD4-positive suppressor cells block allotransplant rejection. J Immunol. 1995;154:6339–6345
  23. Lagaaij EL, Hennemann IP, Ruigrok M, et al. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med. 1989;321:701–705
  24. Brunner-La Rocca HP, Schneider J, Kunzli A, Turina M, Kiowski W. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation. 1998;65:538–543

 This work was funded by grants from the British Heart Foundation and Novartis Pharmaceutical Corporation.

PII: S1053-2498(08)00043-0

doi: 10.1016/j.healun.2008.01.015

The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 450-456 , April 2008

Article Tools

* Image Usage & Resolution